Schinecker
Biotech

Roche CEO gives 3 reasons for sitting out Big Pharma M&A spree

While other Big Pharmas embarked on a frenzy of acquisitions, Roche’s CEO explained to Fierce why the Swiss drugmaker is sitting this round out.
James Waldron Apr 23, 2026 5:18am
Paul Hudson

Sanofi CFO defends Hudson's legacy, accepts R&D ‘setbacks’

Apr 23, 2026 4:04am
3 bioprocessing trendsand the critical enabler thats quietly driving them

3 bioprocessing trends—and the critical enabler that’s quietly driving them

Brought to you by Savillex
Close-up of shredded document

Lilly reneges on remainder of Rigel RIPK1 deal

Apr 22, 2026 3:00pm
Yu Lu-Fierce Biotechjpg

How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients

Brought to you by WuXi AppTec
Merck booth at AACR 2026
Favicon Fierce Pharma

Merck goes with Google for AI push, strikes $1B enterprise deal

Apr 22, 2026 10:12am
More News

AACR: NCI leader assures researchers that ‘funding is strong’

Apr 22, 2026 10:00am

Novartis narrows anticoagulant's focus after losing to Eliquis

Apr 22, 2026 4:00am

Roche unpacks death imbalance in multiple sclerosis ph. 3 trials

Apr 21, 2026 7:15pm

Kyverna’s full SPS data set stage for first autoimmune CAR-T nod

Apr 21, 2026 6:45pm